THE COMBATING ANTIBIOTIC RESISTANT BACTERIA BIOPHARMACEUTICAL ACCELERATOR ‘CARB-X' (360G-Wellcome-208608_Z_17_Z)
The Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) brings together leaders from industry, philanthropy, government and academia. It is a collaboration between the Biomedical Advanced Research and Development Authority (“BARDA”), the National Institute of Allergy and Infectious Diseases (“NIAID”), both within the US Department of Health and Human Services, and the Trustees of Boston University (“BU”). The international partnership will support a suite of products through early preclinical development. CARB-X aims to get products to a stage where private or public investors can then take them forward.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
Amount Awarded | 124959820 |
Applicant Surname | Outterson |
Approval Committee | Internal Decision Panel |
Award Date | 2017-05-15T00:00:00+00:00 |
Financial Year | 2016/17 |
Grant Programme: Title | Discretionary award – DRI |
Internal ID | 208608/Z/17/Z |
Lead Applicant | Prof Kevin Outterson |
Partnership Value | 124959820 |
Planned Dates: End Date | 2023-12-31T00:00:00+00:00 |
Planned Dates: Start Date | 2017-04-01T00:00:00+00:00 |
Recipient Org: Country | United States |
Region | International |